title: The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.
abstract: BACKGROUND
  The Ocular Hypertension Treatment Study (OHTS) has shown that topical ocular hypotensive medication is effective in delaying or preventing the onset of primary open-angle glaucoma (POAG) in individuals with elevated intraocular pressure (ocular hypertension) and no evidence of glaucomatous damage.
  
  
  OBJECTIVE
  To describe baseline demographic and clinical factors that predict which participants in the OHTS developed POAG.
  
  
  METHODS
  Baseline demographic and clinical data were collected prior to randomization except for corneal thickness measurements, which were performed during follow-up. Proportional hazards models were used to identify factors that predicted which participants in the OHTS developed POAG.
  
  
  RESULTS
  In univariate analyses, baseline factors that predicted the development of POAG included older age, race (African American), sex (male), larger vertical cup-disc ratio, larger horizontal cup-disc ratio, higher intraocular pressure, greater Humphrey visual field pattern standard deviation, heart disease, and thinner central corneal measurement. In multivariate analyses, baseline factors that predicted the development of POAG included older age, larger vertical or horizontal cup-disc ratio, higher intraocular pressure, greater pattern standard deviation, and thinner central corneal measurement.
  
  
  CONCLUSIONS
  Baseline age, vertical and horizontal cup-disc ratio, pattern standard deviation, and intraocular pressure were good predictors for the onset of POAG in the OHTS. Central corneal thickness was found to be a powerful predictor for the development of POAG.
authors.affiliation: OHTS Coordinating Center, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Box 8203, 660 South Euclid, St Louis, MO 63110, USA. mae@vrcc.wustl.edu
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
authors.forename: Julia A
authors.initials: JA
authors.lastname: Beiser
authors.forename: James D
authors.initials: JD
authors.lastname: Brandt
authors.forename: Dale K
authors.initials: DK
authors.lastname: Heuer
authors.forename: Eve J
authors.initials: EJ
authors.lastname: Higginbotham
authors.forename: Chris A
authors.initials: CA
authors.lastname: Johnson
authors.forename: John L
authors.initials: JL
authors.lastname: Keltner
authors.forename: J Philip
authors.initials: JP
authors.lastname: Miller
authors.forename: Richard K
authors.initials: RK
authors.lastname: Parrish
authors.forename: M Roy
authors.initials: MR
authors.lastname: Wilson
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003315:Cornea / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000208:ethnology / Q000517:prevention & control; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000208:ethnology / Q000517:prevention & control; D009898:Optic Disk / Q000473:pathology; D016016:Proportional Hazards Models; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents